EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Feasibility and Safety of Elexir, an External Trigeminal Nerve Electrical Stimulator for the Acute Treatment of Migraine

Soo-Im Jang, Soohyun Cho, Mi Ji Lee

Headache and Pain Research · 31.10.2026 · 27 (3) · 193-203

DOI: 10.62087/hpr.2026.0041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache and Pain Research, erschienen am 31.10.2026. Verfasst von Soo-Im Jang und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Medical Device Development Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

External trigeminal nerve stimulation (eTNS) is a noninvasive neuromodulation technique used to treat migraine. This study evaluated the feasibility and safety of Elexir®, a newly developed eTNS device, for the acute treatment of migraine at home.

Methods

This prospective, randomized, sham-controlled postmarketing study enrolled participants with migraine who reported 2–8 attacks per month. Participants were assigned 1:1 to verum or sham stimulation and instructed to use Elexir® at home for 60 minutes during an eligible migraine attack. Feasibility of home use was assessed in terms of per-protocol use and treatment completion at both the participant and session levels; session completion was defined by 60 (±5)-minute stimulation recorded in the device log. Assessments also included adverse events (AEs) and exploratory efficacy outcomes: changes in pain intensity, pain freedom and relief, and resolution of associated symptoms.

Results

Of the 100 randomized participants, 79 formed the home-use population. Within this population, 78 (98.7%; 95% confidence interval [CI], 93.2%–99.8%) used Elexir® during an eligible migraine attack, and 75 (94.9%; 95% CI, 87.7%–98.0%) completed at least one session. Of the 139 treatment sessions conducted at home, 103 (74.1%; 95% CI, 66.2%–80.7%) were completed within the protocol-defined duration. Ten participants (10.0%) reported AEs and eight participants (8.0%) reported device-related AEs. No serious device-related AEs were observed. The groups did not differ significantly in exploratory efficacy outcomes.

Conclusion

These findings support the feasibility of using Elexir® for the acute treatment of migraine; no serious device-related AEs were observed. Further studies are required to support efficacy.

Förderung

  • Korea Medical Device Development Fund

Zitieren

APA

Jang, S., Cho, S., & Lee, M. J. (2026). Feasibility and Safety of Elexir, an External Trigeminal Nerve Electrical Stimulator for the Acute Treatment of Migraine. Headache and Pain Research, 27(3), 193-203. https://doi.org/10.62087/hpr.2026.0041

Vancouver

Jang S, Cho S, Lee MJ. Feasibility and Safety of Elexir, an External Trigeminal Nerve Electrical Stimulator for the Acute Treatment of Migraine. Headache and Pain Research. 2026;27(3):193-203. doi:10.62087/hpr.2026.0041

BibTeX
@article{Jang2026,
  author = {Jang, Soo-Im and Cho, Soohyun and Lee, Mi Ji},
  title = {Feasibility and Safety of Elexir, an External Trigeminal Nerve Electrical Stimulator for the Acute Treatment of Migraine},
  journal = {Headache and Pain Research},
  year = {2026},
  volume = {27},
  number = {3},
  pages = {193--203},
  doi = {10.62087/hpr.2026.0041}
}
Kostenlos starten →